Cencora (COR) Q4 2026 Earnings Call Transcript

Cencora reported fiscal 2026 revenue of $337.4 billion, up 5%, adjusted diluted EPS of $17.97, up 12.3%, and adjusted operating income growth of 14%. For fiscal 2027, it guided to adjusted EPS of $19.40–$19.75 (8%–10% growth, or 10%–12% excluding the anticipated MWI-Covetrus merger impact) and specialty pharmaceutical and provider services operating income growth of 18%–21%; divestitures and the merger are expected to weigh on reported revenue growth by about 150 basis points. The company raised its quarterly dividend 10% to $0.66 per share and plans $1.25 billion of fiscal 2027 share repurchases, while forecasting $3.5 billion of adjusted free cash flow.

Analysis

The key investment question is whether specialty growth converts into durable incremental profit, not whether it lifts reported revenue. GLP-1 and other high-dollar therapies can inflate distributor sales without equivalent earnings leverage, while manufacturer price cuts can suppress reported growth without a matching profit hit. The more important proof point is sustained specialty operating-income growth after the OneOncology acquisition anniversary effects roll off.

The new segments improve transparency, but do not themselves change economics. A real re-rating requires evidence that integrated logistics, distribution, and practice-management capabilities improve retention, capture more services per therapy, or support attractive returns on the MSO investments. Conversely, the MSO mix increases exposure to physician economics and reimbursement; growth targets are vulnerable if practice acquisition or provider profitability weakens.

Near term, first-quarter delivery against the roughly $4.55 EPS expectation is the test, with customer volume shifts and the distribution segment’s modest growth guidance the main execution sensitivities. Over 1–3 months, monitor segment results and closing/timing updates on portfolio exits; over 6–18 months, focus on organic specialty growth, post-acquisition returns, and whether elevated investment supports cash conversion. The $1 billion capex plan and debt repayment compete with buybacks for capital, so headline EPS growth should not be treated as equivalent to improved free-cash-flow growth.

Contrarian view: the market may overvalue specialty revenue scale while underweighting the low-margin distribution base and integration burden. Cigna’s disclosed wholesale-distribution initiative is a competitive watch item, not yet a quantified earnings threat; assess it only as details emerge.

Key Decisions for Investors

• Favor a measured long in COR on weakness rather than chase an earnings-day move; reassess after Q1 results. The upside case is delivery of specialty profit growth and evidence of MSO platform returns; the downside is execution slippage or weaker cash conversion.
• Use segment operating income—not consolidated revenue—as the thesis checkpoint. Falsify the constructive view if specialty growth falls materially short of guidance, or if distribution growth remains weak beyond the disclosed customer-volume and FX pressures.
• Track adjusted free cash flow against the approximately $3.5 billion outlook, capex execution, and the planned $1 billion term-loan repayment. A material shortfall or rising leverage would weaken the buyback-supported EPS narrative.
• Keep CI-related competition on watch, not in the base case: verify the scope, launch timing, customer commitments, and economics of Cigna’s wholesale-distribution effort before changing COR exposure.